Takeda Pharmaceutical (TAK) Income from Continuing Operations (2017 - 2026)

Takeda Pharmaceutical's Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 3578379569.35 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 384.49% year-over-year to 3578379569.35 in Q1 2026; TTM through Mar 2026 was 3220240224.17, a 185.37% decrease from a year earlier, with the FY2026 full-year figure at 1010594468.53, down 242.35% from the prior year.
• Income from Continuing Operations slipped to 3578379569.35 in Q1 2026 per TAK's latest filing, from 3519262989.58 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 2776463151.57 in Q3 2025 and bottomed at 3578379569.35 in Q1 2026.
• The 5-year median for Income from Continuing Operations is 1229451754.51 (2024), against an average of 707490015.56.
• Across the five-year window, Income from Continuing Operations surged 297.92% in 2023 and slumped 4440.99% in 2024, its largest moves.
• Year by year, Income from Continuing Operations stood at 673551561.9 in 2022, then tumbled by 96.58% to 23001791.23 in 2023, then slumped by 4440.99% to 998506189.95 in 2024, then tumbled by 252.45% to 3519262989.58 in 2025, then fell by 1.68% to 3578379569.35 in 2026.
• Per Business Quant, the three latest TAK Income from Continuing Operations figures stand at 3578379569.35 (Q1 2026), 3519262989.58 (Q4 2025), and 2776463151.57 (Q3 2025).